Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study

Schizophrenia Research

Volumn 117, Issue 1, 2010, Pages 75-82

  Bresee, Lauren C ^a,b   Majumdar, Sumit R ^a,b   Patten, Scott B ^c,d   Johnson, Jeffrey A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Diabetes; Dyslipidemia; Hypertension; Sex differences

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL STATUS; STROKE;

CANADA; CARDIOVASCULAR DISEASES; DEMOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; PRIMARY HEALTH CARE; RISK FACTORS; SCHIZOPHRENIA;

EID: 75849164666     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.12.016     Document Type: Article

References (33)

1. Blanchard J.F., Ludwig S., Wajda A., et al. Incidence and prevalence of diabetes mellitus in Manitoba, 1986-1991. Diabetes Care 19 8 (1996) 807-811
2. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J., and for the CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr. Res. 90 1-3 (2007) 162-173
3. Brown L.C., Majumdar S.R., Newman S.C., and Johnson J.A. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care 28 5 (2005) 1063-1067
4. Callaghan R.C., Boire M.D., Lazo R.G., McKenzie K., and Cohn T. Schizophrenia and incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr. Res. 115 2-3 (2009) 325-332
5. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada, 2008. Canadian Journal of Diabetes 32 Suppl 1 (2008) S1-S201
6. Canadian Psychiatric Association Working Group. Clinical practice guidelines: treatment of schizophrenia. Can. J. Psychiatry 50 Suppl 1 (2005) 1S-56S
7. Chuang H.T., Mansell C., and Patten S.B. Lifestyle characteristics of psychiatric outpatients. Can. J. Psychiatry 53 4 (2008) 260-266
8. Citrome L.L., and Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann. Pharmacother. 37 12 (2003) 1849-1857
9. Cohn T., Prud'homme D., Streiner D., Kameh H., and Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 49 11 (2004) 753-760
10. Curkendall S.M., Mo J., Glasser D.B., Stang M.R., and Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J. Clin. Psychiatry 65 5 (2004) 715-720
11. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I.G., and Moller H.-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry 24 6 (2009) 412-424
12. Dixon L., Weiden P., Delahanty J., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26 4 (2000) 903-912
13. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
14. Gianfrancesco F., White R., Wang R.H., and Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 23 4 (2003) 328-335
15. Goldner E.M., Hsu L., Waraich P., and Somers J.M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can. J. Psychiatry 47 9 (2002) 833-843
16. Hux J.E., Ivis F., Flintoff V., and Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25 3 (2002) 512-516
17. Johnson J.A., Vermeulen S.U., and Hugel G. Background and methods. Alberta Diabetes Atlas 2007 (2007), Institute of Health Economics, Edmonton, Canada 1-10
18. Johnstone J., Eurich D.T., Majumdar S.R., Jin Y., and Marrie T.J. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine 87 6 (2008) 329-334
19. Kisely S., Smith M., Lawrence D., Cox M., Campbell L.A., and Maaten S. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 176 6 (2007) 779-784
20. Lambert B.L., Cunningham F.E., Miller D.R., Dalack G.W., and Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am. J. Epidemiol. 164 7 (2006) 672-681
21. McCreadie R.G., and on behalf of the Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia. Br. J. Psychiatry 183 6 (2003) 534-539
22. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 1 (2005) 19-32
23. Morrato E.H., Newcomer J.W., Allen R.R., and Valuck R.J. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry 69 2 (2008) 316-322
24. Munk Laursen T., Munk-Olsen T., Agerbo E., Gasse C., and Mortensen P.B. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch. Gen. Psychiatry 66 7 (2009) 713-720
25. Nasrallah H.A., Meyer J.M., Goff D.C., et al. Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 86 1-3 (2006) 15-22
26. Newman S.C., and Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can. J. Psychiatry 36 4 (1991) 239-245
27. Pilote L., Dasgupta K., Guru V., et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 176 6 (2007) S1-S44
28. Rawson N.S.B., Malcolm E., and D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles. Soc. Psychiatry Psychiatr. Epidemiol. 32 4 (1997) 191-199
29. Redelmeier D.A., Tan S.H., and Booth G.L. The treatment of unrelated disorders in patients with chronic medical diseases. N. Eng. J. Med. 338 21 (1998) 1516-1520
30. Statistics Canada. Census of Population. Available at (2006). http://www12.statcan.ca/census-recensement/2006/dp-pd/hlt/97-550/Index.c fm?TPL=P1C&Page=RETR&LANG=Eng&T=101 Accessed August 17, 2009
31. Tu K., Campbell N.R.C., Chen Z.L., Cauch-Dudek K.J., and McAlister F.A. Accuracy of administrative databases in identifying patients with hypertension. Open Med. 1 1 (2007) 18-26
32. Weber N.S., Cowan D.N., Millikan A.M., and Niebuhr D.W. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr. Serv. 60 8 (2009) 1059-1067
33. Willi C., Bodenmann P., Ghali W.A., Faris P.D., and Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298 22 (2007) 2654-2664